Synonyms: Aleve™, Anaprox™, Naprosyn™
Therapy Type: Small Molecule
Target Type: Inflammation
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Company: Procter & Gamble, Roche Products (Ireland) Limited
Approved for: Over the counter drug for reduction of pain, fever, inflammation, and stiffness.
The mechanism of action of naproxen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals. The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity.
No Available References
No Available Further Reading